Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis

被引：27

作者：

Clifford, K ^{[1
]}

Huck, W ^{[1
]}

Shan, M ^{[1
]}

Tosiello, R ^{[1
]}

Echols, RM ^{[1
]}

Heyd, A ^{[1
]}

机构：

[1] Bayer Corp, Pharmaceut Div, W Haven, CT USA

来源：

ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY | 1999年 / 108卷 / 04期

关键词：

acute bacterial sinusitis; ciprofloxacin; clarithromycin;

D O I：

10.1177/000348949910800408

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

This multicenter, randomized, double-blind trial compared the efficacy and safety of ciprofloxacin (CIP; 500 mg twice daily for 10 days, placebo for 4 days) to those of clarithromycin (CLARI; 500 mg twice daily for 14 days) in 560 adults with clinically documented and radiologically confirmed acute sinusitis. Of 457 efficacy-valid adults (236 CIP, 221 CLARI), clinical resolution plus improvement at the end of therapy was 84% for CIP-treated patients compared to 91% of CLARI recipients (CI95 =-0.131, -0.013). At the 1-month follow-up, more than twice as many CLARI-treated patients, 18 (10%), experienced a relapse, compared to 7 (4%) CLP treated patients. The combined clinical response analyses (end of therapy and I-month follow-up) demonstrated that CIP and CLARI were statistically equivalent (CI95 = -0.106, 0.044). Diarrhea, nausea, headache, and dizziness were the most frequently reported drug-related adverse events in both treatment groups; diarrhea and taste perversion were reported more frequently among CLARI recipients. Zn summary, the combined end of therapy and follow-up clinical evaluation analyses revealed that CIP and CLARI were equally effective in the management of acute sinusitis, although twice as many relapses were reported among CLARI recipients.

引用

页码：360 / 367

页数：8